Adicet Bio, Inc. Common Stock ACET
Analyst Ratings
- Consensus
- Buy — 4 Buy · 0 Hold · 0 Sell (4 analysts)
- Avg. Price Target
- $40.25 (+533.9% upside)
Key Stats
- Today's Range
- $6.25 – $7.96
- 50-Day Range
- $6.25 – $9.97
- 52-Week Range
- $6.01 – $17.44
- Volume
- 2.15 million shs
- Average Volume
- 218K shs
- Market Cap
- $59.45 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 0.49
- Price / Sales
- —
Short Interest
- Short Interest
- 13.28%
- Days to Cover
- 4.92
Financials (TTM)
- Revenue
- —
- Net Income
- $-98,974,000
- Net Margin
- —
- Return on Equity
- -82.38%
- Debt-to-Equity
- —
About Adicet Bio, Inc. Common Stock
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
Related Stocks
Compare head-to-head: ACET vs LLY·ACET vs JNJ·ACET vs ABBV·ACET vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.